Dr. Michaelis on Treating Patients With Myelofibrosis and Anemia

Video

Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.

Laura C. Michaelis, MD, associate professor of medicine, Division of Hematology and Oncology, Medical College of Wisconsin, discusses the treatment of patients with myelofibrosis and anemia.

It is common for patients with myelofibrosis to present with anemia, says Michaelis. Notably, treatment with ruxolitinib (Jakafi) may exacerbate anemia in this patient population.

Combining ruxolitinib with an erythropoiesis-stimulating agent like darbepoetin alfa (Aranesp), or an androgen agent like danazol (Danocrine) may mitigate anemia in some patients.

Additionally, some patients with myelofibrosis and anemia have extramedullary hematopoiesis resulting from an enlarged spleen. Patients receiving ruxolitinib may see a rise in their hemoglobin as their spleen shrinks despite the drug’s myelosuppressive effect, concludes Michaelis.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,